by Osteoporosis treatment involves medications that help slow bone loss and maintain bone density in patients. Oral bisphosphonates, hormone therapy, selective estrogen receptor modulators (SERMs), and monoclonal antibodies are some commonly used drugs. They work by reducing the rate of bone resorption and increasing bone formation. The global demand for such drugs is rising due to the growing prevalence of osteoporosis, primarily in elderly women.
The Global Osteoporosis Treatment Market is estimated to be valued at US$ 14.91 Bn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period from 2024 to 2031.
Key Takeaways
Key players operating in the Osteoporosis Treatment are Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck and Co., Inc., GSK plc., Pfizer Inc., Enzene Biosciences, Apotex Inc. The increasing geriatric population and higher risk of osteoporosis among the elderly are major factors driving the growth of this market. According to the United Nations, the population aged 60 years and above is expected to double by 2050 and reach 2 billion.
Rising incidences of osteoporosis owing to sedentary lifestyles and lack of physical activity is fueling the Osteoporosis Treatment Market Growth. It is estimated that 1 in 3 women and 1 in 5 men over the age of 50 years in the U.S. will experience osteoporotic fractures. The increased focus on preventing fractures through medication is boosting the adoption of osteoporosis drugs globally.
Leading players are actively expanding their presence in developing countries through acquisitions and collaborations. For instance, in 2021, Teva Pharmaceuticals announced the acquisition of Anda, Inc., a distributor of generic and specialty medications in the U.S. This acquisition strengthened Teva’s commercial footprint worldwide.
Market key trends
The demand for anabolic drugs for osteoporosis treatment is growing rapidly. They help in increasing the bone formation rate instead of just reducing bone loss. For example, romosozumab gained FDA approval in 2019 and recorded strong sales as it showed greater efficacy over existing therapeutics like bisphosphonates in increasing bone mineral density levels. Their superior efficacy over traditional antiresorptive drugs is expected to augment their uptake in the osteoporosis treatment market.
Porter’s Analysis
Threat of new entrants: Low barrier for new entrants to introduce generic substitutes of Osteoporosis Treatment Market Analysis. However, R&D costs for innovative products are high.
Bargaining power of buyers: Individual consumers have low bargaining power due to few treatment alternatives. However, larger buyers have higher bargaining power.
Bargaining power of suppliers: Suppliers of active ingredients have moderate bargaining power due to technical expertise required for manufacturing. Suppliers of finished drugs have low bargaining power.
Threat of new substitutes: Emerging biologics offer alternatives, but substitutes are limited due to few options in late-stage clinical trials.
Competitive rivalry: High competition due to generic dominance, pricing pressures, and me-too products. However, ongoing patent expiries may intensify competition.
Geographical regions
North America accounts for the largest share of the osteoporosis treatment market, in terms of value, followed by Europe. This is attributed to the increasing elderly population in both regions which are more susceptible to osteoporosis. The presence of sophisticated healthcare infrastructure and high acceptance of novel drugs further support market growth.
Asia Pacific region is poised to witness the fastest growth for osteoporosis treatment market during the forecast period. This is attributed to increasing healthcare spending, large patient population base, and growing awareness about osteoporosis treatment. Additionally, rising standards of living and changing lifestyles leading to increased calcium and Vitamin D deficiencies also drive the demand for osteoporosis treatment in the Asia Pacific region.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Alice Mutum
Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights. LinkedIn
